Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep-Oct;28(5):436-444.
doi: 10.4103/ijem.ijem_45_24. Epub 2024 Sep 4.

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis

Deep Dutta  1 , Lakshmi Nagendra  2 , B G Harish  3 , Meha Sharma  4 , Ameya Joshi  5 , Basavanagowdappa Hathur  6 , Abm Kamrul-Hasan  7
Affiliations
Review

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis

Deep Dutta et al. Indian J Endocrinol Metab. 2024 Sep-Oct.

Abstract

No meta-analysis has analysed role of cagrilintide as weight-loss medication in obese individuals. Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator. Primary outcomes were changes in body weight; secondary outcomes were alterations in glycemia, lipids, and adverse events. From 678 articles, data from 3 RCTs involving 430 individuals were analysed. At 20-32 weeks, patients receiving Cagrisema weekly had significantly greater percentage [mean difference (MD)-9.07% (95%CI: -11.91, -6.23); P < 0.00001;I 2 = 96%] and absolute [MD-9.11 kg (95%CI: -12.84, -5.39); P < 0.00001; I 2 = 98%] weight-loss, compared to semaglutide 2.4 mg weekly. At 26-32 weeks, cagrilintide 2.4 mg had a similar percentage [MD - 1.83% (95%CI: -4.08, -0.42); P = 0.11; I 2 = 98%] and absolute [MD - 1.88 kg (95%CI: -4.23,0.47); P = 0.12; I 2 = 98%] weight-loss, compared to semaglutide/liraglutide. Treatment-emergent and serious adverse events were comparable between groups. Gastrointestinal adverse events and vomiting were significantly higher with Cagrisema compared to semaglutide. Vomiting was significantly lower with cagrilintide compared to semaglutide/liraglutide. Cagrisema outperforms semaglutide regarding weight loss. Cagrilintide shows comparable weight loss to semaglutide/liraglutide with significantly lower vomiting.

Keywords: Cagrilintide; cagrisema; meta-analysis; obesity; weight loss.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart elaborating on study retrieval and inclusion in the meta-analysis
Figure 2
Figure 2
Forest plot highlighting the impact of (a): Cagrisema 2.4 mg/2.4 mg on percent reduction in body weight as compared to semaglutide 2.4 mg; (b): Cagrilintide 2.4 mg on percent reduction in body weight as compared to semaglutide 2.4 mg/liraglutide 3 mg; (c): Cagrisema 2.4 mg/2.4 mg on absolute reduction in body weight (kg) as compared to semaglutide 2.4 mg; (d): Cagrilintide 2.4 mg on absolute reduction in body weight as compared to semaglutide 2.4 mg/liraglutide 3 mg; (e): Cagrisema 2.4 mg/2.4 mg on HbA1c as compared to semaglutide 2.4 mg; (f): Cagrilintide 2.4 mg on HbA1c as compared to semaglutide 2.4 mg/liraglutide 3 mg; (g): Cagrisema 2.4 mg/2.4 mg on fasting plasma glucose as compared to semaglutide 2.4 mg; (h): Cagrilintide 2.4 mg on fasting plasma glucose as compared to semaglutide 2.4 mg/liraglutide 3 mg
See this image and copyright information in PMC

References

    1. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22:1–203. - PubMed
    1. Dutta D, Jaisani R, Khandelwal D, Ghosh S, Malhotra R, Kalra S. Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and euglycemia in diabesity: A real-world experience. Indian J Endocr Metab. 2019;23:460–7. - PMC - PubMed
    1. Miras AD, le Roux CW. Mechanisms underlying weight loss after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2013;10:575–84. - PubMed
    1. Boyle CN, Lutz TA, Le Foll C. Amylin—its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab. 2018;8:203–10. - PMC - PubMed
    1. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31:1816–23. - PMC - PubMed

LinkOut - more resources